Lawrence Steinman

Publication Details

  • Anaphylaxis to a self-peptide in the absence of mast cells or histamine LABORATORY INVESTIGATION Musio, S., Pedotti, P., Mantegazza, R., Ohtsu, H., Boon, L., Steinman, L., Galli, S. J., Pedotti, R. 2009; 89 (4): 398-405

    Abstract:

    Induction of T helper 1 (Th1) to Th2 deviation through administration of self- or altered self-peptides holds promise for treatment of autoimmunity. However, administration of self-peptides in models of autoimmunity can result in anaphylactic reactions. Although both IgE and IgG1 antibodies might be involved in the development of anaphylaxis to myelin peptides in experimental autoimmune encephalomyelitis in mice, the effector cells and molecules involved are not fully understood. Here we show that systemic anaphylaxis to the self-antigen myelin oligodendrocyte glycoprotein (MOG) 35-55 can occur in mice lacking mast cells (Kit(W)/Kit(W-v) mice) or histamine (histidine decarboxylase-deficient mice), but is prevented in mice lacking IL-4. Treatment of mice with CV6209, a platelet-activating factor antagonist, slightly reduced the incidence of anaphylaxis to self-MOG35-55 in this model, but more effectively protected mice against anaphylaxis to this peptide when self-MOG35-55 was administered in a different immunization protocol that omitted the use of Bordetella pertussis toxin as an adjuvant at the time of immunization. Thus, anaphylactic reactions to self-MOG can occur in the absence of mast cells or histamine, key elements of the classical IgE-, mast cell-, and histamine-dependent pathway of anaphylaxis.

    View details for DOI 10.1038/labinvest.2009.4

    View details for Web of Science ID 000264680900003

    View details for PubMedID 19188909

Stanford Medicine Resources:

Footer Links: